Make the right decisions with data you can trust
Instructions  for  attendees   <ul><li>Due to the High number of attendees :  </li></ul><ul><li>Before starting  </li></ul...
<ul><li>Predicting Drug Candidates Safety : </li></ul><ul><li>the Role and Usage of Knowledge Bases </li></ul>03/12/2010 C...
Agenda <ul><li>Aureus Sciences  </li></ul><ul><li>Build Knowledge Base for Safety Prediction  </li></ul><ul><ul><li>Genera...
Aureus at a Glance <ul><ul><li>Aureus is a knowledge and information management solutions provider for the Life Science in...
<ul><ul><li>To help our customers in the Life Science Industry to develop new innovative and safe drugs  </li></ul></ul><u...
Aureus Value Proposition <ul><ul><li>We offer a unique combination of scientific, IT, and knowledge management assets and ...
Aureus Selected Customers &  Main projects «  KnowTox  »
Safety and  Adverse Effects 31/03/11 Cliquez ici pour changer le texte Every year about 2 million patients in the United S...
DDI and Safety Problem? We need Predictive tools for safety assessment Examples of drugs withdrawn because of CYP-related ...
Aureus Approach for Safety Prediction 31/03/11 Cliquez ici pour changer le texte
Standardization ≠
Unstructured date vs Structured knowledge base <ul><li>Articles   Patents </li></ul><ul><li>Simulation studies </li></ul><...
Quality Control: cross validation CHEMICAL MANUAL QUALITY CONTROL BIOLOGICAL MANUAL QUALITY CONTROL SCORE >5%  NO NEW  CRO...
Quality Control : Statistical Approach Sql request: Definition of the set of data responding to specific criteria (paramet...
Outlier detection: publication error Test 4 Unit discrepency ERROR DETECTION AND CORRECTION
AurSCOPE  Knowledge Databases Target Pharmacological Space 2002 2004 2005 2008 2009 <ul><ul><li>Aureus Terminology, Glossa...
AurSCOPE Knowledge Databases ADME/DDI & TOX Biological Protocols Unique  Ligands Biological Activities Publications Analyz...
31/03/11 Cliquez ici pour changer le texte Usage of Knowledge Base  for Safety Prediction
Prediction Of DDIs : Approach DDI? AurSCOPE ADME/DDI Laboratory Marketed and Preclinical drugs In vitro Data Metabolism In...
Aureus Pharma Confidential All CYPs Data Needed for DDI predictions Competitive inhibition Metabolism by different pathway...
Biological diversity for CYP3A and CYP2D6 inhibitors 31/03/11 Needs of  structured data for retrieving in vitro and in viv...
31/03/11  f m  :   Contribution of a particular enzyme to the overall clearance  AUC ratio Sensitivity  fm(E) Variability...
Prediction Accuracy 31/03/11 MSM : DDI Predict 2009 Edition  MSM DDI predict 2009 Percent Correct (>2 fold DDI <2 fold  no...
Safety Pharmacology 31/03/11 Cliquez ici pour changer le texte Off Targets are unwanted pharmacology activity of drug cand...
Predicting Safety Pharmacology <ul><ul><ul><li>AurPASS® is a ready-to-use software tool running with several SAR bases ext...
Chemical Processing Biological Processing <ul><li>No Peptides </li></ul><ul><li>No mixtures </li></ul><ul><li>Inorganic an...
Predicting Safety Pharmacology on 82 Selected Drugs 277 Ion Channels 82  Selected Molecules
Prediction Accuracy using AurPASS Training Set: 47 938 molecules 517 Activity Types  Mean Accuracy of Prediction: 98%  Tes...
Prediction Accuracy using AurPASS
Aureus Services & New Projects <ul><li>On demand database and searching systems </li></ul><ul><ul><li>Immunogenicity </li>...
Thank you for your attention Aureus Sciences [email_address] 174, Quai de Jemmapes  75010 Paris, FRANCE www.a ureus-scienc...
Upcoming SlideShare
Loading in …5
×

Predicting Drug Candidates Safety : the Role and Usage of Knowledge Bases

2,083 views

Published on

Context
Drug agencies encourage more and more the use of information technologies to improve models to predict the efficacy and safety of submitted drug candidates.
These models require various tools as well as reliable in silico, in vitro and in vivo data. The selection of qualitative experimental data is critical to the efficiency of the predictive models.

Aureus' Solutions
Aureus Sciences has developed a recognized expertise on building knowledge bases with industrial partners in a collaborative approach, for the organization and storage of experimental data to help the pharmaceutical industry improve predictive approaches to drug discovery and development projects.

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,083
On SlideShare
0
From Embeds
0
Number of Embeds
1,067
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • Confidential
  • Confidential
  • Predicting Drug Candidates Safety : the Role and Usage of Knowledge Bases

    1. 1. Make the right decisions with data you can trust
    2. 2. Instructions for attendees <ul><li>Due to the High number of attendees : </li></ul><ul><li>Before starting </li></ul><ul><ul><li>We will mute your microphone during the webinar </li></ul></ul><ul><ul><li>Use your full name for Identification </li></ul></ul><ul><li>During the webinar </li></ul><ul><ul><li>Use the chat for questions </li></ul></ul><ul><li>At the End </li></ul><ul><ul><li>We will answer them either at the end or later on by email. </li></ul></ul>
    3. 3. <ul><li>Predicting Drug Candidates Safety : </li></ul><ul><li>the Role and Usage of Knowledge Bases </li></ul>03/12/2010 CS du 3 décembre 2010
    4. 4. Agenda <ul><li>Aureus Sciences </li></ul><ul><li>Build Knowledge Base for Safety Prediction </li></ul><ul><ul><li>General Approach </li></ul></ul><ul><ul><li>Quality </li></ul></ul><ul><ul><li>Examples : </li></ul></ul><ul><ul><ul><li>Drug drug interactions </li></ul></ul></ul><ul><ul><ul><li>Safety Pharmacology </li></ul></ul></ul><ul><li>Usage of Knowledge Base for Safety Prediction </li></ul><ul><ul><li>Prediction of Drug Drug Interactions </li></ul></ul><ul><ul><li>Prediction of Off target effect </li></ul></ul>
    5. 5. Aureus at a Glance <ul><ul><li>Aureus is a knowledge and information management solutions provider for the Life Science industry located in Paris. </li></ul></ul><ul><ul><li>Over the past 10 years the company has developed a unique knowledge production platform which stores, indexes and organizes critical chemical and bioactivity information including experimental vitro and vivo protocols from the public or private literature. </li></ul></ul><ul><ul><li>Aureus employees 20 high level scientists (PhD and MSc) including scientific and IT project leaders and documentation analysts </li></ul></ul><ul><ul><li>Aureus is funded by institutional investors like CDC Entreprise, AXA Provate Equity, OTC Asset Management and is part of the OSEO Excellence innovation team. </li></ul></ul>
    6. 6. <ul><ul><li>To help our customers in the Life Science Industry to develop new innovative and safe drugs </li></ul></ul><ul><ul><li>by providing </li></ul></ul><ul><ul><li>Solutions which enable them to take the best advantage of the existing scientific knowledge </li></ul></ul><ul><ul><li>and therefore </li></ul></ul><ul><ul><li>Optimize processes, predict new opportunities as well as new risks of their R&D projects </li></ul></ul>AUREUS Mission 03/12/2010 Webinar « Make the right decisions with data you can trust »
    7. 7. Aureus Value Proposition <ul><ul><li>We offer a unique combination of scientific, IT, and knowledge management assets and experience to : </li></ul></ul><ul><ul><ul><li>Assist companies in the Life Science Industry to define the scope and scientifc context of their information needs </li></ul></ul></ul><ul><ul><ul><li>We ensure the development of high level scientific databases focusing on experimental data in the areas of medicinal chemistry, drug biologics, drug safety, ADME/TOX, pharmacovigilance </li></ul></ul></ul><ul><ul><ul><li>We assist on the integration of such databases in customers IT infrastructure or other software applications for further analysis, predictions or simulations </li></ul></ul></ul><ul><ul><ul><li>We develop applications to mine and visualise the data </li></ul></ul></ul>
    8. 8. Aureus Selected Customers & Main projects «  KnowTox  »
    9. 9. Safety and Adverse Effects 31/03/11 Cliquez ici pour changer le texte Every year about 2 million patients in the United States are affected by a serious adverse drug reaction. This results in approximately 100,000 fatalities, making ADRs the fourth leading cause of death in the U.S. The consequence is a huge burden on national economies, which is estimated to be $136 billion annually in the U.S. Over the past 10 years, 19 broadly used marketed drugs were withdrawn after presenting unexpected severe side effects, with Rofecoxib and Cerivastatin.
    10. 10. DDI and Safety Problem? We need Predictive tools for safety assessment Examples of drugs withdrawn because of CYP-related DDIs See the US Food and Drug Administration (FDA) site ( http://www.fda.gov/medwatch/safety.htm ) for an updated list QTC Prolongation QTC Prolongation QTC Prolongation QTC Prolongation Toxicity Toxicity Toxicity Toxicity
    11. 11. Aureus Approach for Safety Prediction 31/03/11 Cliquez ici pour changer le texte
    12. 12. Standardization ≠
    13. 13. Unstructured date vs Structured knowledge base <ul><li>Articles Patents </li></ul><ul><li>Simulation studies </li></ul><ul><li>Experimental studies </li></ul>
    14. 14. Quality Control: cross validation CHEMICAL MANUAL QUALITY CONTROL BIOLOGICAL MANUAL QUALITY CONTROL SCORE >5% NO NEW CROSS VALIDATION <5% YES Knowledge Database BATCH SAMPLE 50%
    15. 15. Quality Control : Statistical Approach Sql request: Definition of the set of data responding to specific criteria (parameter, protocol, substance, target…) Robust Grubbs Test ISO 5725-2 OUTLIERS Decreased number of false positives Multiplication factor to median
    16. 16. Outlier detection: publication error Test 4 Unit discrepency ERROR DETECTION AND CORRECTION
    17. 17. AurSCOPE Knowledge Databases Target Pharmacological Space 2002 2004 2005 2008 2009 <ul><ul><li>Aureus Terminology, Glossary, Thesaurii </li></ul></ul><ul><ul><li>>70 glossaries and dictionaries, 5-10 taxonomies, >65,000 terms and synonyms, I UPHAR, SwissPROT </li></ul></ul>GPCR Biological Protocols Unique Ligands Biological Activities Publications Analyzed Kinase Ion Channel Nuclear Receptor Protease 146,426 354,323 670,407 1,243,793 10,206 including 6,806 patents 13,303 including 6,966 patents 32,588 including 15,281 patents 4,668 including 2,484 patents 98,439 275,044 4,226 including 1,060 patents 418,202 124,313 186,047 48,500
    18. 18. AurSCOPE Knowledge Databases ADME/DDI & TOX Biological Protocols Unique Ligands Biological Activities Publications Analyzed hERG ADME/DDI Hepatotox <ul><ul><li>Aureus Terminology, Glossary, Thesaurii </li></ul></ul><ul><ul><li>>100 glossaries and dictionaries, 5-10 taxonomies, >65,000 terms and synonyms, I UPHAR, SwissPROT </li></ul></ul>13,887 34,872 compounds including 4,050 metabolites 33,210 462,785 2,291 including 547 Patents 12,165 including 200 FDA Reviews 3,600 Articles (67 patents, 75 FDA Studies) 70,035 845 Drugs
    19. 19. 31/03/11 Cliquez ici pour changer le texte Usage of Knowledge Base for Safety Prediction
    20. 20. Prediction Of DDIs : Approach DDI? AurSCOPE ADME/DDI Laboratory Marketed and Preclinical drugs In vitro Data Metabolism Inhibition PK Data Animal Human In vitro Data Metabolism Inhibition PK Data Human My drug IND Phase 1 Phase 2 Phase 3 NDA Phase 4 Discovery DDI Predict Profile of DDI (~100) In (2-3 minutes)
    21. 21. Aureus Pharma Confidential All CYPs Data Needed for DDI predictions Competitive inhibition Metabolism by different pathways (fm(E)) Mechanism-based inactivation (MBI) Inhibitor concentration [I] at the enzyme active site : - [I]in,max, [I]in,avg, Cmax, Cavg - fraction unbound in plasma (fu b ) - Non equilibrium conditions (Kp,Kb, C/M) CYP3A Inhibition of gut « first pass » metabolism (F’g/Fg) Competitive inhibition Metabolism by different pathways Mechanism-based inactivation (MBI)
    22. 22. Biological diversity for CYP3A and CYP2D6 inhibitors 31/03/11 Needs of structured data for retrieving in vitro and in vivo parameter values
    23. 23. 31/03/11  f m : Contribution of a particular enzyme to the overall clearance AUC ratio Sensitivity fm(E) Variability impact on DDI Predictions
    24. 24. Prediction Accuracy 31/03/11 MSM : DDI Predict 2009 Edition MSM DDI predict 2009 Percent Correct (>2 fold DDI <2 fold no DDI) 81 Percent within two fold 76 Percent under predict 4 Percent over predicted 20 MFE 1.69 RMSE 5
    25. 25. Safety Pharmacology 31/03/11 Cliquez ici pour changer le texte Off Targets are unwanted pharmacology activity of drug candidate on various targets related to adverse effects . The hERG-related K+ channel, the 5-HT2B receptor, or the PXR nuclear hormone receptor are typical examples which fall into this category. Extensive in Vitro Safety Pharmacology Profiling can be quite expensive (in the order of about $3000-$10,000 for a panel of 50-100 targets. To offset this there is increasing interest in in silico methods, which do not require any underlying functional knowledge, to predict possible ADRs
    26. 26. Predicting Safety Pharmacology <ul><ul><ul><li>AurPASS® is a ready-to-use software tool running with several SAR bases extracted from the Aureus knowledge bases. These include GPCR, Kinase, Ion Channel 3 , Nuclear Receptor, Protease, and hERG. Aureus specialists extract the SAR cases continuously and finetune them with the PASS algorithms to provide the highest quality predictions. </li></ul></ul></ul>PASS : P rediction of A ctivity S pectra for S ubstances
    27. 27. Chemical Processing Biological Processing <ul><li>No Peptides </li></ul><ul><li>No mixtures </li></ul><ul><li>Inorganic and metalo-organic removal </li></ul><ul><li>Charge standardization </li></ul><ul><li>Biological protocols </li></ul><ul><li>Target hierarchy </li></ul><ul><li>Target species, cell lines and tissues </li></ul><ul><li>Biological activity parameters </li></ul><ul><li>Ligand action on target </li></ul>Added value of structured data for safety prediction
    28. 28. Predicting Safety Pharmacology on 82 Selected Drugs 277 Ion Channels 82 Selected Molecules
    29. 29. Prediction Accuracy using AurPASS Training Set: 47 938 molecules 517 Activity Types Mean Accuracy of Prediction: 98% Test Set: 2244 molecules 113 Activity types Mean Accuracy of Prediction: 90%
    30. 30. Prediction Accuracy using AurPASS
    31. 31. Aureus Services & New Projects <ul><li>On demand database and searching systems </li></ul><ul><ul><li>Immunogenicity </li></ul></ul><ul><ul><li>Biologics </li></ul></ul><ul><ul><li>Hepatotox </li></ul></ul><ul><ul><li>Cardiotox </li></ul></ul><ul><ul><li>Transporters, etc… </li></ul></ul><ul><li>On demand Reports and Studies </li></ul><ul><ul><li>Target & Compound Reports: Extract and provide specific datasets </li></ul></ul><ul><ul><li>Drug Repositioning Studies (Pharmacology Profiles) </li></ul></ul><ul><ul><li>Drug Drug Interaction Reports </li></ul></ul><ul><li>Strengths </li></ul><ul><ul><li>Great reputation for high quality products and scientific excellence </li></ul></ul><ul><ul><li>“ Data that you can trust” </li></ul></ul><ul><ul><li>Oncology Database </li></ul></ul><ul><ul><li>Inflammation/Allergy/Immunology </li></ul></ul>
    32. 32. Thank you for your attention Aureus Sciences [email_address] 174, Quai de Jemmapes 75010 Paris, FRANCE www.a ureus-sciences.com

    ×